Skip Navigation

Schizophrenia Bulletin 2003 29(1):33-43;
© 2003 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Swartz, M. S.
Right arrow Articles by Haak, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swartz, M. S.
Right arrow Articles by Haak, D. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press

Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial

Marvin S. Swartz, M.D., Diana O. Perkins, M.D., M.P.H., T. Scott Stroup, M.D., M.P.H., Joseph P. McEvoy, M.D., Jennifer M. Nieri, M.S.W., L.C.S.W. and David C. Haak, M.S.
Professor, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center Durham, NC
Associate Professors, Department of Psychiatry, University of North Carolina School of Medicine Chapel Hill, NC
Associate Professors, Department of Psychiatry, University of North Carolina School of Medicine Chapel Hill, NC
Associate Professor, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center
Research Instructor, Department of Psychiatry, University of North Carolina School of Medicine
Research Coordinator, Department of Psychiatry, University of North Carolina School of Medicine

Send reprint requests to Dr. M. Swartz, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3173, Durham, NC 27710; e-mail: marvin.swartz{at}duke.edu

Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.

Keywords: Outcome measures / psychopathology assessment / functional assessment / schizophrenia treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
J. C. West, J. E. Wilk, D. S. Rae, I. S. Muszynski, M. R. Stipec, C. L. Alter, K. E. Sanders, S. Crystal, and D. A. Regier
Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States
Psychiatr Serv, May 1, 2009; 60(5): 601 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup, and J. A. Lieberman
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Schizophr Bull, March 1, 2009; 35(2): 336 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv, May 1, 2008; 59(5): 500 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, G. A. Capuano, R. A. Rosenheck, R. S.E. Keefe, A. L. Miller, I. Belz, et al.
Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study
Am J Psychiatry, March 1, 2007; 164(3): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. S. Swartz, D. O. Perkins, T. S. Stroup, S. M. Davis, G. Capuano, R. A. Rosenheck, F. Reimherr, M. F. McGee, R. S.E. Keefe, J. P. McEvoy, et al.
Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
Am J Psychiatry, March 1, 2007; 164(3): 428 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
A. P. Weiss
Measuring the Impact of Medical Research: Moving From Outputs to Outcomes
Am J Psychiatry, February 1, 2007; 164(2): 206 - 214.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Focus, September 1, 2006; 4(4): 539.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. W. Swanson, M. S. Swartz, R. A. Van Dorn, E. B. Elbogen, H. R. Wagner, R. A. Rosenheck, T. S. Stroup, J. P. McEvoy, and J. A. Lieberman
A National Study of Violent Behavior in Persons With Schizophrenia.
Arch Gen Psychiatry, May 1, 2006; 63(5): 490 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. P. McEvoy, J. A. Lieberman, T. S. Stroup, S. M. Davis, H. Y. Meltzer, R. A. Rosenheck, M. S. Swartz, D. O. Perkins, R. S.E. Keefe, C. E. Davis, et al.
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Am J Psychiatry, April 1, 2006; 163(4): 600 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al.
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Am J Psychiatry, April 1, 2006; 163(4): 611 - 622.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med., September 22, 2005; 353(12): 1209 - 1223.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.